Genelux Corporation Announces First Patient Dosed in Phase 2 Trial Evaluating Systemic Therapy with Olvi-Vec in Non-Small Cell Lung Cancer

Stock Information for Genelux Corporation

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Genelux Corporation

Genelux Corporation Announces New Chief Financial Officer
Genelux Corporation to Participate in a Fireside Chat with H.C. Wainwright
Genelux Corporation Reports Third Quarter 2024 Financial Results and Provides General Business Updates
Genelux Corporation to Participate in Fireside Chat at the Guggenheim Inaugural Healthcare Innovation Conference
Genelux Corporation to Participate in the 2024 Maxim Healthcare Virtual Summit
Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference
Genelux Corporation Reports Second Quarter 2024 Financial Results and Provides General Business Updates
Genelux Corporation to Participate in Fireside Chat at BTIG's Virtual Biotechnology Conference 2024

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.